Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525561 | 1.00 | EPHX2 (0.46) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL1013082 | 0.98 | EPHX2 (0.43) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL1017827 | 0.93 | MGAM (0.42) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL221809 | 0.89 | GAA (0.46) | EPHX2SMN1; SMN2MGAMGAASI | |
| SCHEMBL20599527 | 0.84 | SMN1; SMN2 (0.45) | EPHX2SMN1; SMN2MGAMGAASI | |
| SCHEMBL3656303 | 0.83 | TSHR (0.52) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL22559688 | 0.83 | TSHR (0.52) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL434421 | 0.82 | MGAM (0.52) | SMN1; SMN2MGAMGAASIMGAM2 | |
| SCHEMBL599277 | 0.81 | CES2 (0.55) | EPHX2CES2CES1SMN1; SMN2HDAC8 | |
| SCHEMBL29333109 | 0.81 | CES2 (0.55) | EPHX2CES2CES1SMN1; SMN2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410757-B1 | TAXANE COMPOUNDS | BIO RESEARCH CORPORATION OF YOKOHAMA (JP) | 2002-06-25 | — | — | US | claimed |
| CN-111491935-B | Novel analogs as modulators of androgen and glucocorticoid receptors | 昂科斯特拉公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| EP-3707143-B9 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2023-04-12 | — | — | EP | disclosed |
| EP-3707143-B1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2022-12-28 | — | — | EP | disclosed |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | ONCOSTELLAE, S.L. | 2022-09-27 | — | — | US | disclosed |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE, S.L. (ES) | 2020-10-15 | — | — | US | disclosed |
| EP-3707143-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | Oncostellae, S.L. (ES) | 2020-09-16 | — | — | EP | disclosed |
| CN-111491935-A | Novel analogs as androgen receptor and glucocorticoid receptor modulators | 昂科斯特拉公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-1029857-A1 | Baccatin derivatives and a process for producing the same | Bio Research Corporation of Yokohama (JP) | 2000-08-23 | — | — | EP | disclosed |
| EP-0456073-B1 | Multifunctional compounds having alpha-diazo-beta-ketoester units and sulfonic acid ester units and process for their preparation. | HOECHST AG (DE) | 1995-10-25 | — | — | EP | disclosed |
| EP-0378067-B1 | Positively working radiation-sensitive mixture containing a multifunctional alpha-diazo-beta-keto ester, process for its preparation and a radiation-sensitive recording material containing this mixture | HOECHST AG (DE) | 1995-05-31 | — | — | EP | disclosed |
| EP-0378068-B1 | NEW POLYFUNCTIONAL ALPHA-DIAZO-BETA-KETO ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-31 | — | — | EP | disclosed |
| US-5198322-A | Positively operating radiation-sensitive mixture containing a polyfunctional α-diazo-β-keto ester and radiation-sensitive recording material containing this mixture | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-30 | — | — | US | disclosed |
| US-5191069-A | Photosensitive compounds with heat resistance | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
| EP-0456073-A2 | Multifunctional compounds having alpha-diazo-beta-ketoester units and sulfonic acid ester units and process for their preparation. | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-13 | — | — | EP | disclosed |
| US-4996301-A | Polyfunctional α-diazo-β-keto esters and their use in light-sensitive compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-26 | — | — | US | disclosed |
| EP-0378067-A2 | Positively working radiation-sensitive mixture containing a multifunctional alpha-diazo-beta-keto ester, process for its preparation and a radiation-sensitive recording material containing this mixture | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-07-18 | — | — | EP | disclosed |
| EP-0378068-A1 | New polyfunctional alpha-diazo-beta-keto esters, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | EPHX2 1439/4885CES2 1269/4885CES1 134/4885 |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | NR5A1, AR, NR3C1 | EPHX2 4813/4885CES2 4076/4885CES1 1447/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | EPHX2 708/4885CES2 2000/4885CES1 206/4885 |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | AR, NR5A1, NR3C1 | EPHX2 4814/4885CES2 4177/4885CES1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.